LLY · 8-K · 20260805PR000077

Manufacturing and Capacity

ELI LILLY & Co · 2026-08-05 · Importance 52 · Surprise 42

Lilly committed an additional $4.5 billion to expand manufacturing sites in Indiana. The company also opened its first dedicated genetic medicine facility. The investment is intended to add capacity alongside continued growth in Mounjaro, Zepbound, and the broader obesity and genetic-medicine pipeline. The announcement specifically links new manufacturing capacity coming online with Lilly's future weight-loss medicine strategy.